Sign In
Buy SBS
$5.40
-0.130 (-2.35%)
At Close: Jun 03, 2026
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients
08:15am, Wednesday, 30'th Apr 2025
Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI C
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for c
Sabesp: Market's Just Starting To Price The New Playbook
01:55am, Friday, 25'th Apr 2025
SABESP is just beginning to unlock the benefits of privatization, with a bold R$70 billion investment plan through 2030 aimed at full sanitation coverage. Despite macro headwinds in Brazil, SBS ADRs h
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and mi
5 Must-Buy Efficient Stocks Amid Volatile Market Conditions
07:55am, Thursday, 17'th Apr 2025
Invest in companies like ALLT, SBS, LNN, EQBK and GFF to make the most of higher efficiency levels.
Growth Without The Premium: 6 Value Stocks For April
05:00am, Wednesday, 16'th Apr 2025
In this period of extreme market turbulence, large-cap value stocks are outperforming large-cap growth stocks by nearly 8% YTD. This is a seismic shift in the style regime, as mega-cap growth has typi
Sabesp (SBS) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Monday, 14'th Apr 2025
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shor
Sabesp Q4: Privatization Is Making The Company More Agile Every Quarter (Rating Upgrade)
08:37am, Wednesday, 26'th Mar 2025
I am upgrading my recommendation on Sabesp shares from hold to buy due to strong 4Q24 results, showing revenue and profit growth. Despite a lower EBIT due to redundancy provisions, Sabesp's operationa
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (SBS) Q4 2024 Earnings Call Transcript
02:42pm, Tuesday, 25'th Mar 2025
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:SBS ) Q4 2024 Earnings Conference Call March 25, 2025 12:00 PM ET Company Participants Thiago Levy - Investor Relations Director Da
This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indicat
Recent Price Trend in Sabesp (SBS) is Your Friend, Here's Why
09:51am, Monday, 17'th Feb 2025
Sabesp (SBS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "R
Sabesp (SBS) is a Top-Ranked Momentum Stock: Should You Buy?
10:55am, Monday, 03'rd Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Utilities Stocks Lagging Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) This Year?
10:41am, Wednesday, 29'th Jan 2025
Here is how Sabesp (SBS) and Telecom Italia (TIIAY) have performed compared to their sector so far this year.
Is Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) a Great Value Stock Right Now?
11:06am, Tuesday, 07'th Jan 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (
